Background It has been claimed that around 70% of childhood acute lymphoblastic leukemia (ALL) can be cured. One of the important role is high dose methotrexate (HDMTX) administration during the consolidation therapy. Objective To determine the safety and effectiveness of HDMTX in children with ALL. Methods We reviewed patients with ALL in Pantai Indah Kapuk Hospital, Jakarta during the period August 2000 through July 2005 with observation time run through September 2006. Only patients with normal kidney function were allowed to have HDMTX. Besides good hydration and alkalinization, patients were supported with good hygiene (mouth, skin and anal area). MTX was given in loading dose of 10% from the total dose in ½ hour and the rest 23½ hours for 90%. Leucovorin rescue was started 12 hours after discontinuation of 24 hour MTX IV infusion. Leucovorin was given until the MTX concentration reached 0.1 uM/L. Patients were stratified to low, intermediate and high risk groups; 2 gram/m 2 was given to low risk group and 5 gram/m2 to intermediate and high risk groups. Results There were 20 patients eligible for study. All methotrexate steady-state plasma concentrations (MTX Cp ss ) were above 16 uM/ L, and steady state concentration in CSF was always below 0.5 uM/ L for 2 gram/m 2 and above 0.5 uM/L for 5 gram/m 2 doses. All 20 cases went through the procedure with only mild side effects i. e, mild mucositis, anal furuncle and diarrhea, which recovered 2 weeks later. Only 1 high risk case with initial WBC 612X10 9 /L, succumbed after he went through the HDMTX program smoothly and relapsed subsequently during reinduction phase. Conclusion HDMTX can be given safely to ALL patients with normal kidney function with good supportive care. Five gram/m 2 HDMTX effectively treat the minor disease and/or prevent CNS and testicular leukemia. This study has also given an impression that HDMTX may increase event-free survival. [Paediatr Indones 2007;47:1-6].
C
hildhood acute lymphoblastic leukemia (ALL) is one of the most drug-responsive of human malignancy. It is claimed that around 70% of children, even higher (up to 80%) can be cured mainly by chemotherapy and good supportive care. 1, 2 One of the important roles in the increasing EFS (event free survival) rate is high doses methotrexate (HDMTX) program during the consolidation therapy. 3 Clinical trials indicated that single high dose methotrexate (1000 mg/m 2 24 hours infusion) will yield higher concentration of active metabolites of MTXPG (methotrexate polyglutamate) in the blast cells compared to low dose (20-30 mg/m 2 p.o. every 6 hours for 6 doses). 4 Higher concentration of MTXPG in the cell blast of ALL has been proven to give greater antileukemic effect, i.e. inhibition of purine synthetase and reduction of circulating blast cells. 5 Clinical trial in St. Jude Children Hospital indicated that the level of systemic exposure of HDMTX (high dose methotrexate) can have a significant influence on clinical outcome in children with ALL. A significant relation between the steadystate plasma concentration (Cp ss ) of MTX and eventfree survival was observed in the study of children with standard-risk ALL. In Cox proportional hazard regression analysis, patients with MTX Cp ss <16 uM had a significant greater risk of early treatment failure (relapse) when compared to patients with MTX Cp ss >16 uM. 6 This greater risk remained statistically significant in a multivariate analysis including other prognostic factors such as white blood cell count and DNA index. In subsequent study, MTX Cp ss (methotrexate steady state plasma concentration) remained a significant prognostic factor in patient with intermediate risk (i.e. presenting white cell count 10-100X10 9 /L). A similar relationship between MTX Cp s and risk of ALL relapse was also reported by Pediatric Oncology Group trial. 7 Evan et al found that 24-hour infusion of MTX 1000 mg/m 2 combined with 6-MP 50 mg /m 2 and MTX 25 mg/m 2 p.o. give MTX Cp ss 9.3-25.4 mM/L. 8 It is true that the clinical response of T-cell leukemia may differ. However, in a randomized study it was found that HDMTX was superior with 7 year event-free survival for B or T-cell ALL. 5 Research data showed that it takes at least 8 hours after I.V. MTX to reach the "steady state concentration" in the cerebrospinal fluid. 8 Without IT MTX, at least 3 gram/m 2 is needed to reach the therapeutic level 0.5 μM/L for treatment of subclinic invasion of malignant lymphoid cells. 9, 10 The objective of this study was to prove that high dose of MTX can be given safely to ALL patients with normal kidney function with good supportive care. We also wanted to see whether this drug can effectively treat the minor disease, prevent the CNS and testicular leukemia and to increase the EFS with possible cure. Time duration between discontinuation of methotrexate administration and leucovorin rescue discontinu-ation will also be sought for.
Methods
The dose determination of MTX was based on the minimal steady state concentration to reach in plasma 16 μM/L and CSF 0.5 μM/L after HDMTX dose.
MTX dose for low risk ALL
As previously observed, administration of MTX 1 gram/m 2 will yield MTX Cp ss 9.3-25.4 μM/L. We used 24 hour infusion of 2 gram/m 2 MTX for patients with low risk ALL that will yield Cp ss >16 μM/L and MTX steady state cerebrospinal fluid concentration <0.5 ump/L in general. Since most ALL patients from low risk group have no CNS involvement at initial diagnosis, triple IT cytostatics may adequately prevent CNS leukemia.
MTX dose for intermediate and high risk ALL
In patients with intermediate and high risk cases, we frequently encounter subclinical CNS leukemia. Without IT MTX, at least 3 gram/m 2 is needed to reach therapeutic level 0.5 μM/L for treatment of subclinic invasion of malignant lymphoid cells. 9 For those reasons, to guarantee that the level of ³0.5 uM/L can reach cerebrospinal fluid with minimal toxicity, we used with 5 gram/m 2 I.V. MTX for intermediate and high risk groups. In addition, we also added triple IT.
Procedure of HMTX administration
Hydration and alkalinization Hydration and alkalinization was started 12 hours prior to MTX administration. We used 1 / 5 solution (0.2% NaCl) with infusion rate of 120 ml/m 2 /hour and 8.4% NaHCO 3 6 ml/m 2 /hour. Urine output and pH were measured between 7.0-8.0 by measuring urine volume and pH every 4 hours.
Furosemide 0.5-1.0 mg/kgBW was administered if input more than output for 15 ml/kgBW/4 hours, and NaHCO 3 1 ml/hour was given if urine pH <7.0 and reduced 1 ml/hour if the urine pH >8.0. Methotrexate was given 12 hours after hydration and alkalinization with 10% loading dose from the total dose for the first ½ hour followed by 90% of the total dose for the rest 23½ hours.
Intrathecal administration
We gave triple methotrexate, ara-C and hydrocortison simultaneously after loading dose, to reach steady state of MTX concentration in CSF. It usually takes 2 hours after starting of MTX infusion or 2 hours prior to the discontinuation of MTX administration.
The patient was maintained in Trendelenberg position for at least 4 hours.
Leucovorin rescue
Leucovorin 15 mg/m 2 was administered 36 hours after starting hydration or 12 hours after discontinuation of methotrexate administration. Interval administration is 3 hours for 5 doses and then 6 hours until plasma concentration reaches less than 0.1 μM/L. 11 HDMTX was administered to all patients who had gone through the initial induction (induction Ia
We administered HDMTX during consolidation period even though some of them were not in complete remission, but showed much improvement from the initial induction (Induction Ia and Ib). Among them, there were 2 patients with mixed lineage and 1 patient with high risk adolescence, which have showed marked improvement from the initial induction (Blast cell in the marrow above 5%, but less than 20%).
Adjuvant therapy
To reduce or eliminate side effects or complications which may develop during or after HDMTX administration, we administered additional therapies e.g., by maintaining the skin pH at 3-4 with lactoserum and lactic acid, anal pH at 2-3 with 2% acetic acid in Burrow Solution, and mouth gargle with Hexetidine.
Results
There were 20 patients enrolled during the study period, consisted of 10 patients with low risk, 6 with intermediate risk, and 4 with high risk ALL. Te total dose of HDMTX given to low risk groups were 40, to intermediate risk 24, and to high risk groups were 14.
Means of plasma steady state concentration during 24 hour administration are depicted in Figure  1 . Level of plasma concentration ≤ 0.1 uM/L was reached in 36 to 48 hours for all risk groups, which is safe to stop the Leucovorine Rescue Program. Figure 2 .
All patients were discharged if the level of MTX Cp ss ≤ 0.1 uM/L, i.e., between 36-48 hours after discontinuation of 24-hour MTX group infusion. In term of toxicity, for low risk group there were 3 patients developed mild diarrhea after 24-hour infusion of MTX finished, but this improved in 48 hours before the patients being discharged. There were two patients in the intermediate risk group who had mild mucositis in the mouth, and one of the high risk group had furuncle at the anal area (this pateint was treated with oral antibiotic) and showed much improvement. They were sent home 60 hours after the termination of MTX. One of the 20 patients who was diagnosed with T-cell ALL with initial WBC count of 612X10 9 /L, died 5 months after being diagnosed. The patient went through severe tumor lysis syndrome; he had relapse with dominant CD33 in very depressed marrow and sepsis. The observation ranged between 5 months to 72 months with a survival rate of 95%.
Discussion
MTX Cp ss above 16 mMol/L, as it was in our class, was reported to be significantly increased in EFS. Since most ALL with low risk groups have no CNS involvement at the initial diagnosis, we believed that triple IT cytostatics should be adequate to prevent CNS leukemia.
After discontinuation of MTX, the MTX plasma concentration decreased most steeply at the first 6 hours with half-life between 30 to 60 minutes. These are due to hydration, alkalinization and maintaining good urine output (always above 3ml/KgBW/hour). The decrement in the MTX concentration is much faster than that reported previously. 11 This study has given an impression that this procedure can reduce an unnecessary exposure of MTX to the normal tissue. This probably explained the very low/insignificant side effects and effectively improved the remission in our cases.
All MTX concentration in plasma will be at/less than 0.1 mMol/L between 36-48 hours after the discontinuation of MTX administration, which is considered safe to discontinue Leucovorine administration. There were mild side effect observed during methotrexate administration about 2 weeks, after the termination of administration and prior to the next course of HDMTX administration. With hydration, alkalinization, maintaining the urine output at least 3 ml/kgBW/hour and good supportive cares, HDMTX administration is considered very safe to be given to low risk ALL. All our low risk patients during observation of 1 year 8 months to 5 years 4 months are still in remission. This study has shown that HDMTX may increase long term EFS for low risk patients, but the number of patients are too small and the time of observation is too short to draw the definite conclusion.
HDMTX is also safe to be given to intermediate and high risk ALL. 
